University of California, San Francisco
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).
University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.
University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.
Top-decile sponsor footprint
University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,713 total, page 28 of 35
Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast
NCT00788112
Rifabutin Based Therapy for the Eradication of Staphylococcus Aureus Colonization in HIV Infected Adults
NCT00869518
Endothelial Cell Loss After Cataract Surgery
NCT00932191
HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
NCT00905060
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
NCT00843531
Analysis of Blood-based Biomarkers of Asthma
NCT00917787
Low-Cost Contingency Management for Smoking Cessation
NCT01040260
Very Long Term Results After Laparoscopic Retrocolic Antegastric Gastric Bypass
NCT01040507
Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis
NCT00924950
Bilateral Oophorectomy Versus Ovarian Conservation
NCT01007305
Internal Hernias After Laparoscopic Gastric Bypass
NCT01040364
Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection
NCT00879047
Harnessing Health IT for Self-Management Support and Medication Activation in a Medicaid Health Plan
NCT00683020
Comparison of Three Methods of Hemoglobin Monitoring
NCT00792597
Effect of Tool Design on Hand Pain in Dental Practitioners
NCT01332760
Study of Maternal Hepatitis C Infection and Influenza Vaccination in Pregnancy
NCT00810875
Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population
NCT00845416
Laparoscopic Revision From Biliopancreatic Diversion to Gastric Bypass
NCT01041456
Community Based Participatory Research With Immigrant Chinese With Diabetes
NCT00833677
Hemangioma Growth During the First 6 Months of Life
NCT00911781
ICU Patient and Family Comfort Study
NCT00798941
Perforated Marginal Ulcer After Gastric Bypass
NCT01041196
Treating to Target for Patients With Hypertension
NCT01013857
Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)
NCT00862745
Endothelial Function and Vein Graft Remodeling
NCT00831090
Intensive Insulin Therapy in Deceased Donors
NCT01140035
Effectiveness of a Web-based Prevention Program for Postpartum Depression
NCT00816725
Effect of Raltegravir on Endothelial Function in HIV-Infected Patients
NCT00843713
Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer
NCT01010854
Gastric Bypass After Previous Anti-reflux Surgery
NCT01041105
Endoscopic Therapy for Bleeding Marginal Ulcers After Gastric Bypass
NCT01040416
Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis
NCT00819195
Chronic Marginal Ulcers After Gastric Bypass
NCT01041079
Pharmacogenetics of Nicotine Metabolism in African-Americans
NCT00879918
Patient Expectations After Implantable-cardioverter Defibrillator (ICD) Implantation
NCT00845390
Laparoscopic Revision of Jejunoileal Bypass to Gastric Bypass
NCT01040533
Effectiveness of a Behavioral Treatment Program for Attention Deficit Hyperactivity Disorder, Inattentive Type
NCT00834821
Effects of Levetiracetam (Keppra) on Alcohol Consumption
NCT01168687
Disulfiram Interactions With HIV Medications: Clinical Implications
NCT00878306
Sleep Enhancement Training Study for Novice Shiftworkers
NCT00786266
Massage for Pediatric Oncology
NCT00843180
Drug Interaction Study of Rifampin and Warfarin in Healthy Volunteers.
NCT00777855
The Effects of a Yoga Program in Heart Failure Patients
NCT00794027
Treating People With Post-Traumatic Stress Disorder With Cognitive Behavioral Therapy for Insomnia
NCT00881647
Sleep Enhancement Training Study for Experienced Shiftworkers
NCT00786357
Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)
NCT00804128
Dilapan Versus Laminaria
NCT00775983
Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis
NCT00800982
Yoga Breathing for Fatigue in Patients Undergoing Chemotherapy
NCT00982748
ECT/Succinylcholine: Biochemical, Serum and Cardiovascular Changes
NCT00750906
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 193 |
| Phase 2 | 166 |
| Phase 3 | 44 |
| Phase 4 | 152 |
Therapeutic Areas
What is open in the University of California, San Francisco pipeline
272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).
Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (18 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of California, San Francisco: open-pipeline peers nationwide
Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,713 trials (± recruiting share)
- Duke University · 1,725 trials · 11% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 16% open enrollment (± trial volume)
- University of Oregon · 16% recruiting · 63 trials
- Fox Chase Cancer Center · 16% recruiting · 183 trials
- Youngstown State University · 16% recruiting · 19 trials
- ECOG-ACRIN Cancer Research Group · 16% recruiting · 75 trials
Related
What to do with this University of California, San Francisco page
1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.
- 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.